Castle Biosciences, Inc. (CSTL), Wednesday said that its DecisionDx-Melanoma test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
DecisionDx-Melanoma is a gene expression profile (GEP) test used to evaluate the risk of recurrence and metastasis for patients diagnosed with stage I-III cutaneous melanoma.
"DecisionDx-Melanoma provides valuable biological insights that help inform clinicians post-diagnosis decision making based on a patient's individual predicted risk of metastasis," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.